Simvastatin with chemotherapy for triple-negative breast cancer
Treatments studied
Part of Cancer, Skin clinical trials.
This trial studies whether adding simvastatin (a cholesterol medicine) can slow or change how breast cancer spreads in triple-negative breast cancer. It compares outcomes while you receive planned chemotherapy, and you may or may not be taking simvastatin as part of the study treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a woman (or assigned female at birth).
- You have advanced breast cancer that is confirmed as triple-negative from a biopsy test.
- You are planning to receive 8 cycles of AC-T chemotherapy.
- You are older than 18 years.
- You can agree to join the study by signing consent.
- You are not currently pregnant or breastfeeding.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether a short course of an immunotherapy drug (called sintilimab) combined with two standard chemotherapy drugs can shrink tumors before surgery in patients with triple-negative breast cancer. The goal is to see if this combination improves treatment response and outcomes.
This trial tests a combination of an immunotherapy drug (PD-L1 antibody) along with a low-dose oral chemotherapy ('metronomic') called VEX for people with advanced triple-negative breast cancer. The goal is to see if this combination is safe and effective in controlling the cancer.
This trial tests seviteronel together with standard chemotherapy to treat certain types of advanced breast cancer that has spread. It’s looking to see how well the combination works and how safe it is, especially for cancers that are androgen-receptor positive.
This trial studies giving camrelizumab plus apatinib and chemotherapy before surgery for triple-negative breast cancer. The goal is to shrink the tumor and improve outcomes by testing a combination of immune and targeted medicines along with chemotherapy.
This Phase 3 trial compares an “anti-blood-vessel” drug added to chemotherapy versus chemotherapy alone for people with stage II–IIIC triple-negative breast cancer that has been completely removed with surgery. The goal is to see if adding the study drug improves outcomes after surgery (adjuvant treatment).
This trial tests a new combination of chemotherapy and immunotherapy that avoids a class of drugs called anthracyclines, which can be hard on the heart. The goal is to shrink tumors before surgery for people with triple-negative or low-hormone-receptor breast cancer.
Hear when a new Triple Negative Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.